香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 表 明 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 代表董事會 北京市春立正達醫療器械股份有限公司 史文玲 董事長 中 國，北 京，2023年10月17日 截 至 本 公 告 日 期，執 行 董 事 為 史 文 玲 女 士、史 春 寶 先 生、岳 術 俊 女 士 及 解 鳳 寶 先 生；非 執 行 董 事 為 王 鑫 先 生；及 獨 立 非 執 行 董 事 為 姚 立 杰 女 士、翁 杰 先 生 及 黃 德 盛 先 生。 * 僅供識別 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：1858） 董事會會議通告 北京市春立正達醫療器械股份有限公司（「本公司」）之董事會（「董事會」）謹此宣 佈將於2023年10月30日（星 期 一）舉 行 董 事 會 會 議，藉 以（其 中 包 括）批准本公司 及其 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 表 明 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 北京市春立正達醫療器械股份有限公司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （股 份 代 號：1858） 須予披露交易 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） (I)認購北京銀行（大 興 支 行）的結構性存款產品 (II)認購北京銀行（方 莊 支 行）的結構性存款產品 認購結構性存款產品 上市規則之涵義 由於北京銀行（方 莊 支 行）結構性存款產品協議4、北 京 銀 行（大 興 支 行）結 構 性存款產品協議及北京銀行（方 莊 支 行）結構性存款產品協議5項下交易的適 用百分比率（按 上 市 規 則 第14.07條 所 界 定）合共超過5%但低於25%，因 此，根 據上市規則第14章，該 ...

关于 北京市春立正达医疗器械股份有限公司 2023 年第一次临时股东大会的法律意见书 北京市万商天勤律师事务所 北京市朝阳区建国门外大街 8 号北京国际财源中心 A 座 32 层 100022 电话: +86 10 82255588 www.vtlaw.cn 北京 深圳 上海 成都 武汉 西安 长沙 杭州 海口 南京 广州 昆明 香港(联营) 北京市万商天勤律师事务所 关于北京市春立正达医疗器械股份有限公司 2023 年第一次临时股东大会的 法律意见书 致：北京市春立正达医疗器械股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》及中国证券监督管理委 员会《上市公司股东大会规则（2022 年修订）》（以下称"《股东大会规则》"）等法律、 法规和规范性文件的规定，北京市万商天勤律师事务所（以下称"本所"）接受北京市 春立正达医疗器械股份有限公司（以下称"公司"）的委托，指派律师参加公司 2023 年第一次临时股东大会（以下称"本次股东大会"），并出具法律意见。 本所律师同意将本法律意见书随公司本次股东大会决议一并予以公告，并依法对 本法律意见书承担相应的责任。 本所律师根据《股东大会规则》第五条的 ...

证券代码：688236 证券简称：春立医疗 公告编号：2023-039 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2023 年 10 月 10 日 （二） 股东大会召开的地点：北京市通州区通州经济开发区南区鑫觅西二路 10 号公司 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有 表决权数量的情况： | 1、出席会议的股东和代理人人数 | 4 | | --- | --- | | 普通股股东人数 | 4 | | 其中：A 股股东人数 | 3 | | 境外上市外资股（H 股）股东人数 | 1 | | 2、出席会议的股东所持有的表决权数量 | 225,615,866 | | 普通股股东所持有表决权数量 | 225,615,866 | | 其中：A 股股东人数 | 210,516,730 | | 境外上市外资股（H 股）股东人数 | 15,099,136 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2023年10月5日 I. 法定/註冊股本變動 本月底法定/註冊股本總額： RMB 383,568,500 第 1 頁 共 6 頁 v 1.0.2 II. 已發行股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | 於香港聯交所上市 (註1) | 是 | | --- | --- | --- | --- | --- | --- | | 證券代號 | 01858 | 說明 | H股 | | | | 上月底結存 | | 95,140,500 | | | | | 增加 / 減少 (-) | | | 0 | | | | 本月底結存 | | 95,140,500 | | | | | 2. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 (註1) | 否 | | --- | --- | --- | --- | --- | --- | | 證券代號 | 688236 ...

Regulatory and Market Position - The company holds 102 medical device registrations in China, including 34 Class III, 21 Class II, and 47 Class I registrations, enhancing its market competitiveness [7]. - In the first half of 2023, the company achieved significant progress in obtaining domestic and international registrations, marking the beginning of an accelerated certification phase [8]. - The orthopedic medical device market in China is experiencing growth due to factors such as an aging population and increased healthcare spending [6]. - The orthopedic implant industry is relatively concentrated, with high entry barriers due to strict regulatory measures and high-quality product requirements [6]. - The company actively responds to national procurement policies to ensure stable supply and compliance in the orthopedic joint sector [6]. - The orthopedic implant market is dominated by multinational companies, but domestic firms are expected to increase market share through improved product offerings [6]. Product Development and Innovation - The company aims to expand its product portfolio to meet diverse market and clinical needs, thereby enhancing its overall competitiveness [7]. - The company has established itself as a leader in the domestic orthopedic industry, focusing on the research and development of artificial joint prosthetics, with over 20 years of experience [9]. - As of June 30, 2023, the company has received government funding for multiple R&D projects, including the development of high-quality medical metal powder materials and clinical research on minimally invasive knee joint prosthetics [9]. - The company has successfully launched several new products, including vitamin E high-crosslinked polyethylene hip and knee products, marking a significant advancement in the domestic market [11]. - The company has expanded its product line in the spinal sector, obtaining registration certificates for self-stabilizing cervical interbody fusion devices and artificial vertebral body fixation systems [11]. - In the trauma field, the company has received approvals for multiple products, including bone plates and intramedullary nails, enhancing its orthopedic product offerings [11]. - The company has made significant strides in sports medicine, obtaining registration for seven new products, which will boost sales revenue in this segment [11]. - The company has entered the oral care market, acquiring registration for orthodontic products and maxillofacial surgical devices, establishing a comprehensive oral product line [11]. Financial Performance - As of June 30, 2023, the company's operating revenue was approximately RMB 540.71 million, a decrease of 5.37% compared to RMB 571.39 million in the same period last year [17]. - The company's gross profit for the six months ended June 30, 2023, was approximately RMB 391.41 million, down 8.08% from RMB 425.80 million year-on-year, resulting in a gross margin of 72.39% [19]. - The company achieved a net profit of approximately RMB 125.99 million for the six months ended June 30, 2023, a decline of 19.74% from RMB 156.98 million in the same period last year [25]. - Sales expenses increased by 7.66% to approximately RMB 166.89 million due to the gradual recovery of market activities post-pandemic [20]. - The company's current assets decreased from approximately RMB 957.19 million as of December 31, 2022, to approximately RMB 855.12 million as of June 30, 2023 [26]. - The company reported a total of RMB 154,599,501.79 in special reserves for the period [80]. Research and Development - Research and development expenses for the first half of 2023 amounted to approximately RMB 74.57 million, representing a 3.15% increase from RMB 72.29 million in the previous year, accounting for 13.79% of revenue [22]. - The company plans to enhance its product range by optimizing existing products and investing more resources in new product development, particularly in the orthopedic medical device sector [40]. - The company is focusing on developing customized orthopedic implants, which include traditional and assembled customized joint prosthetics [41]. - The company is committed to enhancing its market share by strengthening production operations and internal management while expanding into new markets [41]. Corporate Governance and Compliance - The board of directors is committed to maintaining high standards of corporate governance, believing it is crucial for protecting shareholder interests and enhancing corporate value [46]. - The company has adopted the "Standard Code" for securities transactions by directors and supervisors, confirming compliance for the six months ending June 30, 2023 [47]. - The audit committee has reviewed the consolidated financial statements for the six months ending June 30, 2023, including the accounting principles and practices used [48]. - The financial report was approved by the board of directors on August 30, 2023, indicating ongoing compliance with accounting standards [86]. Shareholder Information - As of June 30, 2023, Mr. Shi Chunbao holds 113,685,435 A shares, representing 39.42% of the relevant class of share capital and 29.64% of the total share capital [50]. - Ms. Yue Shujun also holds 95,447,900 A shares, representing 33.09% of the relevant class of share capital and 24.88% of the total share capital [50]. - CITIC Securities Co., Ltd. holds 19,750,000 A shares, representing 6.85% of the relevant class of share capital and 5.15% of the total share capital [52]. - FIL Limited holds 7,791,000 H shares, representing 8.19% of the relevant class of share capital and 2.03% of the total share capital [53]. - The total number of issued shares as of June 30, 2023, is 383,568,500, comprising 288,428,000 A shares and 95,140,500 H shares [54]. Assets and Liabilities - As of June 30, 2023, total assets amounted to RMB 3,472,457,994.37, an increase from RMB 3,409,766,690.91 as of December 31, 2022, reflecting a growth of approximately 1.84% [57]. - Total liabilities reached RMB 745,055,516.20, up from RMB 690,066,911.19, marking an increase of around 7.97% [60]. - Shareholders' equity totaled RMB 2,727,402,478.17, compared to RMB 2,719,699,779.72 at the end of 2022, showing a slight increase of about 0.1% [60]. - The company's long-term liabilities, including lease liabilities, were reported at RMB 625,860.19, with deferred income tax liabilities increasing to RMB 10,439,311.12 from RMB 7,879,291.52 [58]. - The total current liabilities increased to RMB 650,355,916.53 from RMB 595,804,539.93, representing a growth of approximately 9.15% [59]. Cash Flow and Investments - The net cash outflow from operating activities was approximately RMB 38.97 million as of June 30, 2023, mainly due to increased cash received from sales [34]. - The net cash flow from operating activities is negative at RMB -38,971,893.80, an improvement from RMB -81,512,729.59 in the same period last year [71]. - The net cash flow from investing activities is RMB -63,934,501.16, an improvement from RMB -510,359,121.29 in the previous year [72]. - Cash inflow from investment activities totaled RMB 1,537,695,421.37, compared to RMB 926,741,308.22 in the previous year, indicating a significant increase [75]. - The company redeemed all structured deposit products with a total investment of RMB 30 million from Bank of Beijing, yielding an actual return of RMB 313.27 thousand at an annualized return of 3.15% [36]. Inventory and Receivables - The company reported a total inventory at the end of the period is RMB 408,488,947.36, an increase from RMB 280,772,410.70 at the beginning of the period, representing a growth of 45.5% [173]. - The raw materials inventory increased to RMB 152,517,933.68 from RMB 85,077,518.73, reflecting an increase of 79.2% [173]. - The finished goods inventory at the end of the period is RMB 199,661,078.26, up from RMB 142,731,746.75, indicating a rise of 39.7% [173]. - Accounts receivable at the end of the period totaled RMB 578,927,472.41, up from RMB 488,746,494.02, indicating an increase of approximately 18.5% [155]. - The provision for bad debts was RMB 60,772,707.03, which is 9.50% of the total accounts receivable, compared to 51,949,099.75 and 9.61% at the beginning of the period [156]. Taxation and Deferred Tax - The company maintains a corporate income tax rate of 15%, benefiting from high-tech enterprise status valid until 2023 [151]. - The total deferred tax assets at the end of the period amounted to CNY 8,156,997.68, an increase from CNY 3,130,616.33 at the beginning of the period, reflecting a growth of approximately 160% [197]. - The total deferred tax liabilities at the end of the period were CNY 10,439,311.12, up from CNY 7,879,291.52 at the beginning, representing an increase of about 32% [198]. Accounting Policies and Practices - The financial statements are prepared in accordance with the Chinese Accounting Standards, ensuring transparency and accuracy in financial reporting [86]. - The company recognizes revenue when the customer obtains control of the related goods or services, which is determined by specific indicators such as the transfer of legal ownership and the acceptance of goods [134]. - The company assesses the useful life of intangible assets based on contractual or legal rights without a clear term, and reviews these annually [125]. - The company recognizes expected credit losses for financial assets measured at amortized cost and those classified at fair value through other comprehensive income, including receivables and lease receivables [106].

重要内容提示： 证券代码：688236 证券简称：春立医疗 公告编号：2023-038 北京市春立正达医疗器械股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年第一次临时股东大会 召开日期时间：2023 年 10 月 10 日 14 点 00 分 召开地点：北京市通州区通州经济开发区南区鑫觅西二路 10 号公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 10 月 10 日 至 2023 年 10 月 10 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2023年10月10日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） ...

北京市春立正达医疗器械股份有限公司 2023 年第一次临时股东大会会议资料 证券代码：688236 证券简称：春立医疗 北京市春立正达医疗器械股份有限公司 2023 年第一次临时股东大会 会议资料 二〇二三年九月 1 北京市春立正达医疗器械股份有限公司 2023 年第一次临时股东大会会议资料 2023 年第一次临时股东大会会议资料 目录 | 2023 年第一次临时股东大会会议须知 | | 3 | | --- | --- | --- | | 2023 年第一次临时股东大会会议议程 | | 5 | | 议案一：《关于部分募投项目变更的议案》 | | 6 | 2 北京市春立正达医疗器械股份有限公司 2023 年第一次临时股东大会会议资料 2023 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则（2022 年修订）》以及《公司章程》、《股东大会议事规则》 等相关规定，特制定北京市春立正达医疗器械股份有限公司（以下简称"公司"） 2023 年第一次临时股东大会会议须知： 一、为 ...

华泰联合证券有限责任公司 关于北京市春立正达医疗器械股份有限公司 2023 年半年度持续督导跟踪报告 | 保荐机构名称： | 被保荐公司简称： | | --- | --- | | 华泰联合证券有限责任公司 | 北京市春立正达医疗器械股份有限公司 | | 保荐代表人姓名：张畅 | 联系电话：010-56839300 | | 保荐代表人姓名：茹涛 | 联系电话：021-38966546 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为北京市春立正达医疗器械股份有 限公司（以下简称"春立医疗"、"公司"或"发行人"）首次 A 股公开发行股 票的保荐机构，对春立医疗进行持续督导，并出具本持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 无 二、重大风险事项 （一）经营风险 1、核心材料依赖境外单一供应商的风险 公司陶瓷关节假体产品所用到的陶瓷球头、陶瓷内衬均自 CeramTec GmbH 采购。CeramTec GmbH 是一家总部位于德国的先进陶瓷材料供应商，包括 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2023年9月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 01858 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 2. 股份分類 | 普通股 | 股份類別 | A | ...